本帖最后由 老马 于 2012-1-13 21:20 编辑 . I8 d) r& ~+ J' C6 p
/ a6 J! |0 H7 k, w5 o" c爱必妥和阿瓦斯丁的比较% Z' F* \& I+ H+ [0 ?& |. `
& v3 v# R5 f! r5 T7 _http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! q- l& w& a& v- |$ k; o
P% h+ b! _) y) E+ V0 R
0 U& w* z; K, q, @0 C/ f" Shttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( J/ s/ Q" n( l% h
==================================================$ C0 T* X+ {5 `6 ~3 B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- R2 T3 ~ M, _, ePatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.0 P8 F) I* `$ x4 }9 {7 K8 B1 x
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 F9 z- c X3 ?8 L
|